[go: up one dir, main page]

CL2016001134A1 - Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento. - Google Patents

Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.

Info

Publication number
CL2016001134A1
CL2016001134A1 CL2016001134A CL2016001134A CL2016001134A1 CL 2016001134 A1 CL2016001134 A1 CL 2016001134A1 CL 2016001134 A CL2016001134 A CL 2016001134A CL 2016001134 A CL2016001134 A CL 2016001134A CL 2016001134 A1 CL2016001134 A1 CL 2016001134A1
Authority
CL
Chile
Prior art keywords
car
domain
cell
endodomain
nucleic acid
Prior art date
Application number
CL2016001134A
Other languages
English (en)
Inventor
Martin Pule
Khai Kong
Shaun Cordoba
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320573A external-priority patent/GB201320573D0/en
Priority claimed from GB201410934A external-priority patent/GB201410934D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2016001134A1 publication Critical patent/CL2016001134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Se describe una célula T que coexpresa un primer receptor antigénico (CAR) y un segundo CAR en la superficie celular, y cada CAR comprende: (i) un dominio de unión a antígenos, (ii) un espaciador, (iii) un dominio transmembranal; y (iv) un endodominio, donde los dominios de unión a antígeno del primer y segundo CAR se unen a diferentes antígenos, y en donde uno del primer o segundo CAR es un CAR activador que comprende un endodominio activador, y el otro CAR es un CAR inhibitorio que comprende un endodominio inhibitorio de ligación encendida que comprende un dominio de tirosina fosfatasa de una proteína tirosina fosfatasa que contiene el dominio homologo Src (SH2); una secuencia de ácido nucleico que codifica dichos primer y segundo CAR; un kit que comprende las secuencia de ácido nucleico que codifican dichos primer y segundo CAR; un kit que comprende un primer y un segundo vector que comprenden dichas secuencias de ácido nucleico; un método para elaborar dicha célula T; una composición farmacéutica que comprende dichas células T y un vehículo, diluyente o excipiente farmacéuticamente aceptable; el uso de diha composición farmacéutica para preparar un medicamento útil para tratar y/o prevenir el cáncer; el uso de dichas células T para preparar un medicamento para tratar y/o prevenir el cáncer; una célula asesina natural (NK) que coexpresa un primer receptor antigénico (CAR) y un segundo CAR en la superficie celular, y cada CAR comprende: (i) un dominio de unión a antígenos, (ii) un espaciador, (iii) un dominio transmembranal; y (iv) un endodominio, donde los dominios de unión a antígenos del primer y segundo CAR se unen a diferentes antígenos, y en donde uno del primer o segundo CAR es un CAR activador que comprende un endodominio activador, y el otro CAR es un CAR inhibitorio que comprende un endodominio inhibitorio de ligación encendida que comprende un dominio de tirosina fosfatasa de una proteína tirosina fosfatasa que contiene el dominio homologo Src (SH2); y una composición de células que comprende las células T que expresan CAR y/o células NK que expresan CAR de acuerdo con la reivindicación 20, elaborada al transducir una muestra de sangre ex vivo con un ácido nucleico que codifica el primer y segundo CAR.
CL2016001134A 2013-11-21 2016-05-12 Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento. CL2016001134A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201320573A GB201320573D0 (en) 2013-11-21 2013-11-21 T Cell
GB201410934A GB201410934D0 (en) 2014-06-19 2014-06-19 T cell

Publications (1)

Publication Number Publication Date
CL2016001134A1 true CL2016001134A1 (es) 2017-05-19

Family

ID=52003983

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016001135A CL2016001135A1 (es) 2013-11-21 2016-05-12 Celula que coexpresa un primer receptor antigenico quimerico (car) y un segundo car en la superficie celular, y cada car comprende un dominio de unión a antígenos, un espaciador, un dominio transmembranal y un endodominio.
CL2016001134A CL2016001134A1 (es) 2013-11-21 2016-05-12 Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016001135A CL2016001135A1 (es) 2013-11-21 2016-05-12 Celula que coexpresa un primer receptor antigenico quimerico (car) y un segundo car en la superficie celular, y cada car comprende un dominio de unión a antígenos, un espaciador, un dominio transmembranal y un endodominio.

Country Status (19)

Country Link
US (10) US10172886B2 (es)
EP (6) EP3071222B1 (es)
JP (4) JP6538684B2 (es)
KR (2) KR101991555B1 (es)
CN (2) CN105792840B (es)
AU (2) AU2014351557B2 (es)
BR (2) BR112016011460A2 (es)
CA (2) CA2930215C (es)
CL (2) CL2016001135A1 (es)
DK (2) DK3071223T3 (es)
ES (2) ES2861501T3 (es)
HU (1) HUE051523T2 (es)
IL (2) IL245573B (es)
MX (2) MX373687B (es)
PL (2) PL3071222T3 (es)
PT (2) PT3071223T (es)
RU (2) RU2717984C2 (es)
SG (2) SG11201603479TA (es)
WO (3) WO2015075468A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2419143B8 (en) 2009-04-13 2018-06-27 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN120617536A (zh) 2013-09-18 2025-09-12 奥拉生物科学公司 用于诊断和治疗肿瘤的病毒样颗粒缀合物
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
MX373687B (es) 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
JP6943568B2 (ja) * 2013-12-06 2021-10-06 アメリカ合衆国 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
US10494434B2 (en) 2013-12-20 2019-12-03 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
KR102463529B1 (ko) 2014-04-10 2022-11-07 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 약물 관련 트랜스진 발현
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
AU2015367317A1 (en) * 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
CA3224507A1 (en) 2014-12-24 2016-06-30 Autolus Limited Cell co-expressing chimeric antigen receptors binding cd19 and cd22
JP6912386B2 (ja) * 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
KR102329836B1 (ko) 2015-01-26 2021-11-19 셀렉티스 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
SG11201706236SA (en) 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
KR102632082B1 (ko) * 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
EP3286225B1 (en) * 2015-04-23 2020-07-01 Baylor College of Medicine Cd5 chimeric antigen receptor for adoptive t cell therapy
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
US11827904B2 (en) * 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
CA2986030A1 (en) * 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
AU2016271147B2 (en) * 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP4424326A3 (en) * 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
WO2017222593A1 (en) * 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
CN115058395B (zh) * 2015-06-25 2025-07-18 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
JP7162530B2 (ja) 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US20180264038A1 (en) 2015-09-28 2018-09-20 Regents Of The University Of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
EP3368656A4 (en) * 2015-10-30 2019-07-17 The United States of America, as represented by the secretary, Department of Health and Human Services TARGETED CANCER THERAPY
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017149515A1 (en) * 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2017193059A1 (en) 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells
EP3458077A4 (en) * 2016-05-17 2020-04-01 Chimera Bioengineering Inc. METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
JP7160482B2 (ja) 2016-09-02 2022-10-25 レンティジェン・テクノロジー・インコーポレイテッド Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法
GB2570063B (en) * 2016-09-09 2022-11-02 Crage Medical Co Ltd Fusion protein and applications thereof
US11219646B2 (en) * 2016-09-30 2022-01-11 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
JP2019535262A (ja) * 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
CA3048648A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation T cells expressing a chimeric antigen receptor
WO2018144535A1 (en) * 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
SG11201908337VA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
JP7356354B2 (ja) * 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
CN110621694A (zh) * 2017-05-15 2019-12-27 奥托路斯有限公司 包含嵌合抗原受体(car)的细胞
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
AU2018313939A1 (en) 2017-08-10 2020-02-06 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
FI3688155T3 (fi) 2017-09-28 2023-03-30 Immpact Bio Ltd Universaali alusta inhibitorisen kimeerisen antigeenireseptorin (icar) valmistamiseksi
JP7710644B2 (ja) * 2017-10-12 2025-07-22 アイセル・ジーン・セラピューティクス・インコーポレイテッド 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
CA3078963A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201803079D0 (en) * 2018-02-26 2018-04-11 Autolus Ltd Cell
WO2019177986A1 (en) * 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
SG11202011080QA (en) 2018-05-11 2020-12-30 Crispr Therapeutics Ag Methods and compositions for treating cancer
JP7335272B2 (ja) 2018-05-15 2023-08-29 オートラス リミテッド キメラ抗原受容体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
KR102839381B1 (ko) 2018-08-29 2025-07-28 내셔널 유니버시티 오브 싱가포르 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법
ES3012752T3 (en) 2018-09-27 2025-04-10 Autolus Ltd Chimeric antigen receptor
JP2022504191A (ja) * 2018-10-05 2022-01-13 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体（ｃａｒ）群
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
CA3117419A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021006968A (es) 2018-12-12 2021-10-13 Kite Pharma Inc Antígeno quimérico y receptores de las células t, y métodos de uso.
EP3914268B1 (en) 2019-01-23 2025-10-15 Miltenyi Biotec B.V. & Co. KG A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
CA3151385A1 (en) 2019-05-01 2020-11-05 Pact Pharma, Inc. Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
EP3969482A1 (en) * 2019-05-16 2022-03-23 University of Washington Lockr-mediated recruitment of car t cells
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
JP2022546315A (ja) * 2019-08-20 2022-11-04 センティ バイオサイエンシズ インコーポレイテッド キメラ抑制性受容体
WO2021044213A2 (en) * 2019-09-05 2021-03-11 Migal-galilee Research Institute Ltd. Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CN114929752A (zh) * 2019-10-08 2022-08-19 省卫生服务机构 嵌合细胞因子受体
EP4093429A4 (en) * 2019-11-26 2024-05-22 University of Utah Research Foundation COMPOSITIONS AND METHODS FOR REGULATION OF HLA CLASS I ON TUMOR CELLS
BR112022009679A2 (pt) 2019-11-26 2022-08-09 Novartis Ag Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
MX2022006962A (es) 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
TW202146436A (zh) * 2020-02-20 2021-12-16 美商聖堤生物科技股份有限公司 抑制性嵌合受體架構
EP4107175A4 (en) * 2020-02-20 2024-03-20 Senti Biosciences, Inc. ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
MX2023002041A (es) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
LT4058474T (lt) 2020-08-20 2024-08-26 A2 Biotherapeutics, Inc. Kompozicijos ir būdai, skirti gydyti egfr atžvilgiu teigiamas vėžio formas
US11976297B2 (en) 2020-09-21 2024-05-07 A2 Biotherapeutics, Inc. Engineered immune cells with receptor cross-talk
EP4228672A4 (en) * 2020-10-15 2024-12-18 Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR INHIBITING NATURAL KILLER CELL RECEPTOR
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
CA3207958A1 (en) 2021-02-16 2022-08-25 Julyun OH Compositions and methods for treating her2 positive cancers
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2022251377A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
WO2023023602A1 (en) * 2021-08-19 2023-02-23 Boan Boston Llc Fusion proteins for dephosphorylating proteins that regulate t cell activation through the tcr signaling pathway
GB202112923D0 (en) 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
JP5312721B2 (ja) * 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
AU2002360424A1 (en) * 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US9206440B2 (en) * 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
KR102466666B1 (ko) 2013-03-15 2022-11-15 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
MX373687B (es) 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
KR102463529B1 (ko) * 2014-04-10 2022-11-07 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 약물 관련 트랜스진 발현
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11885806B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells

Also Published As

Publication number Publication date
IL245573A0 (en) 2016-06-30
JP2019041775A (ja) 2019-03-22
CN105848673B (zh) 2020-02-14
US20200016203A1 (en) 2020-01-16
ES2832586T3 (es) 2021-06-10
IL245572B (en) 2019-02-28
AU2014351558B2 (en) 2018-08-02
HK1223553A1 (en) 2017-08-04
KR20160085348A (ko) 2016-07-15
WO2015075470A1 (en) 2015-05-28
EP3071222A1 (en) 2016-09-28
PL3071223T3 (pl) 2021-08-16
PL3071222T3 (pl) 2021-04-19
CA2929984A1 (en) 2015-05-28
RU2016124280A (ru) 2017-12-26
PT3071222T (pt) 2020-11-20
MX377283B (es) 2025-03-07
WO2015075468A1 (en) 2015-05-28
JP6538684B2 (ja) 2019-07-03
CL2016001135A1 (es) 2016-12-23
SG11201603484PA (en) 2016-05-30
CN105792840A (zh) 2016-07-20
WO2015075469A1 (en) 2015-05-28
US20210154229A1 (en) 2021-05-27
MX373687B (es) 2020-07-07
DK3071222T3 (da) 2020-11-16
EP3071221A1 (en) 2016-09-28
AU2014351557A1 (en) 2016-05-26
EP3071223B1 (en) 2021-01-13
US10172886B2 (en) 2019-01-08
CA2930215C (en) 2021-04-27
SG11201603479TA (en) 2016-05-30
US20200016204A1 (en) 2020-01-16
CN105792840B (zh) 2020-10-13
US20210187026A1 (en) 2021-06-24
MX2016006057A (es) 2016-11-14
JP2021045172A (ja) 2021-03-25
BR112016011459A2 (pt) 2017-09-26
CA2929984C (en) 2021-05-18
RU2717984C2 (ru) 2020-03-27
KR101991555B1 (ko) 2019-06-20
IL245573B (en) 2018-11-29
JP2016538854A (ja) 2016-12-15
KR101962524B1 (ko) 2019-07-17
NZ719859A (en) 2020-11-27
CA2930215A1 (en) 2015-05-28
DK3071223T3 (da) 2021-03-29
EP3858378A1 (en) 2021-08-04
JP2016538855A (ja) 2016-12-15
US10172885B2 (en) 2019-01-08
EP3858379A1 (en) 2021-08-04
AU2014351557B2 (en) 2019-04-18
HK1223554A1 (en) 2017-08-04
US20160289293A1 (en) 2016-10-06
MX2016006303A (es) 2016-11-07
PT3071223T (pt) 2021-03-25
EP3071222B1 (en) 2020-10-21
US20160289294A1 (en) 2016-10-06
ES2861501T3 (es) 2021-10-06
AU2014351558A1 (en) 2016-05-26
KR20160085347A (ko) 2016-07-15
US20190038672A1 (en) 2019-02-07
US20160296562A1 (en) 2016-10-13
EP3626261A1 (en) 2020-03-25
HUE051523T2 (hu) 2021-03-01
JP6433498B2 (ja) 2018-12-05
BR112016011460A2 (pt) 2017-09-26
CN105848673A (zh) 2016-08-10
RU2732236C2 (ru) 2020-09-14
EP3071223A1 (en) 2016-09-28
US20240033289A1 (en) 2024-02-01
IL245572A0 (en) 2016-06-30
RU2016124278A (ru) 2017-12-22
US20240033292A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
EA202092202A1 (ru) Конструкции антител к ror
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EA202091710A1 (ru) Антитела против cd73 и способы их применения
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
AR095432A1 (es) Proteínas de unión a antígeno
CL2013001468A1 (es) Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
MX2011000011A (es) Anticuerpos estables y solubles que inhiben el vegf.
AR095374A1 (es) Moléculas de unión para bcma y cd3